BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics develops RAS-targeting small molecules for KRAS-driven cancers.
10-QSep 18Latest SEC filing, period to Jun 30
Aug 11Latest story
August 2026
Sign inSign inBridgeBio Oncology Therapeutics develops RAS-targeting small molecules for KRAS-driven cancers.